|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP2B2 |
Gene summary for ATP2B2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP2B2 | Gene ID | 491 |
| Gene name | ATPase plasma membrane Ca2+ transporting 2 | |
| Gene Alias | PMCA2 | |
| Cytomap | 3p25.3 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | A0A024R2K6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 491 | ATP2B2 | NAFLD1 | Human | Liver | NAFLD | 8.52e-14 | 8.99e-01 | -0.04 |
| 491 | ATP2B2 | S41 | Human | Liver | Cirrhotic | 1.22e-05 | 5.15e-01 | -0.0343 |
| 491 | ATP2B2 | HCC1_Meng | Human | Liver | HCC | 3.45e-53 | 7.70e-02 | 0.0246 |
| 491 | ATP2B2 | HCC2 | Human | Liver | HCC | 4.73e-04 | 2.03e+00 | 0.5341 |
| 491 | ATP2B2 | S027 | Human | Liver | HCC | 4.59e-02 | 4.67e-01 | 0.2446 |
| 491 | ATP2B2 | S028 | Human | Liver | HCC | 1.86e-05 | 3.15e-01 | 0.2503 |
| 491 | ATP2B2 | S029 | Human | Liver | HCC | 6.93e-12 | 6.52e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATP2B2 | SNV | Missense_Mutation | rs775707408 | c.113N>A | p.Arg38Gln | p.R38Q | Q01814 | protein_coding | deleterious(0.01) | benign(0.433) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| ATP2B2 | SNV | Missense_Mutation | novel | c.2634N>A | p.Phe878Leu | p.F878L | Q01814 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP2B2 | SNV | Missense_Mutation | c.823N>A | p.Ala275Thr | p.A275T | Q01814 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ATP2B2 | SNV | Missense_Mutation | rs765910999 | c.3659N>T | p.Thr1220Met | p.T1220M | Q01814 | protein_coding | deleterious_low_confidence(0.02) | benign(0.301) | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ATP2B2 | SNV | Missense_Mutation | rs774434270 | c.1946N>A | p.Arg649Gln | p.R649Q | Q01814 | protein_coding | tolerated(0.15) | possibly_damaging(0.471) | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ATP2B2 | SNV | Missense_Mutation | c.2580C>A | p.Ser860Arg | p.S860R | Q01814 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| ATP2B2 | SNV | Missense_Mutation | c.2579G>C | p.Ser860Thr | p.S860T | Q01814 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| ATP2B2 | SNV | Missense_Mutation | c.2548G>A | p.Asp850Asn | p.D850N | Q01814 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| ATP2B2 | insertion | In_Frame_Ins | novel | c.1482_1483insAGTCTCTTGAGGCCT | p.Thr494_Ala495insSerLeuLeuArgPro | p.T494_A495insSLLRP | Q01814 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ATP2B2 | insertion | Frame_Shift_Ins | novel | c.804_805insAATGAAAATCCACCCAGCATAGATTCATCCAAGACATGGGCAG | p.Gly269AsnfsTer40 | p.G269Nfs*40 | Q01814 | protein_coding | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |